ESTRO 2024 - Abstract Book

S2612

Clinical - Urology

ESTRO 2024

1. Robb, Plank and Middleton. 2014. Assessing the Efficiency and Consistency of Daily Image-guided Radiation Therapy in a Modern Radiotherapy Centre. Journal of Medical Imaging and Radiation Sciences. 45, 2, 72-78. https://doi.org/10.1016/j.jmir.2013.10.005 2. Nightingale, Conroy, Elliott, Coyle, Wylie and Choudhury. 2017. A national survey of current practices of preparation and management of radical prostate radiotherapy patients during treatment. Radiography. 23, 2, 87-93. https://doi.org/10.1016/j.radi.2017.01.003 3. McParland, Pearson, Wong, Sigur, Stenger and Tyldesley. 2014. Quantifying daily variation in volume and dose to the prostate, rectum and bladder using cone-beam computerised tomography. Journal of Radiotherapy in Practice. 13, 1, 79-86. https://doi.org/10.1017/S1460396913000216

3058

Digital Poster

PSMA-guided management of prostate cancer patients relapsing after prostatectomy and prostate-bed RT

Valeria Chiofalo 1 , Diego Bongiovanni 1 , Giuseppe Carlo Iorio 1 , Cristiano Grossi 1 , Sara Bartoncini 1 , Veronica Richetto 2 , Ilaria Bonavero 1 , Fabio Menegatti 1 , Edoardo Gozzelino 1 , Erica Maria Cuffini 1 , Giuliana Petruzzellis 1 , Marzia Cerrato 1 , Bruna Lo Zito 1 , Chiara Casale 1 , Francesca Catena 1 , Eulalie Joelle Tondji Ngassam 1 , Ramona Parise 1 , Mario Levis 1 , Guido Rovera 3 , Serena Grimaldi 3 , Marco Oderda 4 , Paolo Gontero 4 , Umberto Ricardi 1 1 University of Turin, Department of Oncology, Turin, Italy. 2 University of Turin, Department of Medical Physics, Turin, Italy. 3 University of Turin, Department of Medical Sciences, Nuclear Medicine, Turin, Italy. 4 University of Turin, Department of Surgical Sciences, Urology, Turin, Italy

Purpose/Objective:

To evaluate the impact of PSMA-PET in the management of recurrent prostate cancer (PCa) patients (pts) following radical prostatectomy (RP) and prostate-bed (P-bed) RT.

Material/Methods:

This analysis is part of a prospective, open label, observational, single-centre study testing the PSMA-PET performance in recurrent hormone-sensitive PCa pts. Pts with biochemical recurrence (BCR) following RP + prostate bed (P-bed) RT (adjuvant or salvage) were staged with PSMA-PET. Only pN0-pNx were included in the analysis. The previous P-bed RT treatments were not preceded by a PSMA-PET. ADT was not allowed at BCR detection prior to the PSMA-PET exam. In case of negative PSMA-PET, pts were followed-up/observed and are not part of the present analysis. In case of positive PSMA-PET, the prescription of metastases-directed therapy (MDT) or ADT was at physician discretion. Endpoints of this analysis were: biochemical progression-free survival (bPFS) following any treatment after positive PSMA-PET; and ADT-free survival in pts treated exclusively with SBRT-based MDT.